2 completed, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow naluzotan: new trials by email Literature Review of naluzotan trials Research Report on naluzotan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRX-00023 Therapy in Localization-Related Epilepsy PRX-00023, Placebo - Epilepsy, Epilepsy, Temporal Lobe | Phase 2 | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 12 | 2011-01-07 | 2018-12-07 |
| A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder PRX-00023, Placebo for PRX-00023 - Major Depressive Disorder (MDD) | Phase 2 | Completed | Epix Pharmaceuticals, Inc. | 330 | 2007-03-01 | 2007-11-14 |
| A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD) PRX-00023 - Anxiety Disorders | Phase 3 | Completed | Epix Pharmaceuticals, Inc. | 310 | 2005-08-01 | 2008-04-03 |
Anxiety Disorders (1) · Depression (1) · Depressive Disorder, Major (1) · Epilepsies, Partial (1) · Epilepsy (1) · Epilepsy, Temporal Lobe (1)
Epix Pharmaceuticals, Inc. (2) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (3)